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Background: The current standard of care for insomnia includes gamma-aminobutyric acid receptor A (GABAA)
activators, which promote sleep as well as general central nervous system depression. Dual orexin receptor
antagonists (DORAs) represent an alternative mechanism for insomnia treatment that induces somnolence by
blocking the wake-promoting effects of orexin neuropeptides. The current study compares the role and
interdependence of these two mechanisms on their ability to influence sleep architecture and quantitative
electroencephalography (qEEG) spectral profiles across preclinical species.
Results: Active-phase dosing of DORA-22 induced consistent effects on sleep architecture in mice, rats, dogs, and
rhesus monkeys; attenuation of active wake was accompanied by increases in both non─rapid eye movement
(NREM) and rapid eye movement (REM) sleep. Eszopiclone, a representative GABAA receptor modulator, promoted
sleep in rats and rhesus monkeys that was marked by REM sleep suppression, but had inconsistent effects in mice
and paradoxically promoted wakefulness in dogs. Active-phase treatment of rats with DORA-12 similarly promoted
NREM and REM sleep to magnitudes nearly identical to those seen during normal resting-phase sleep following
vehicle treatment, whereas eszopiclone suppressed REM even to levels below those seen during the active phase.
The qEEG changes induced by DORA-12 in rats also resembled normal resting-phase patterns, whereas eszopiclone
induced changes distinct from normal active- or inactive-phase spectra. Co-dosing experiments, as well as studies
in transgenic rats lacking orexin neurons, indicated partial overlap in the mechanism of sleep promotion by orexin
and GABA modulation with the exception of the REM suppression exclusive to GABAA receptor modulation.
Following REM deprivation in mice, eszopiclone further suppressed REM sleep while DORA-22 facilitated recovery
including increased REM sleep.
Conclusion: DORAs promote NREM and importantly REM sleep that is similar in proportion and magnitude to that
seen during the normal resting phase across mammalian animal models. While limited overlap exists between
therapeutic mechanisms, orexin signaling does not appear involved in the REM suppression exhibited by GABAA
receptor modulators. The ability of DORAs to promote proportional NREM and REM sleep following sleep
deprivation suggests that this mechanism may be effective in alleviating recovery from sleep disturbance.
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Currently, most pharmacologic treatments for insomnia
are central nervous system depressants that act by allo-
sterically activating gamma-aminobutyric acid receptor
A (GABAA) [1-4]. More recently, the inhibition of orexin-
mediated arousal has attracted interest as a potential
mechanism for treating insomnia [5,6]. Orexin neurons,
which are active during wakefulness but quiescent during
sleep [7], are localized in the lateral hypothalamus and
project to multiple brain regions, including regions in-
volved with regulating sleep and wakefulness [8]. Several
orexin receptor antagonists (ORAs) have been developed
to interfere with orexin signaling by blocking one or both
orexin receptors (OX1R and OX2R) and have demon-
strated the ability to safely promote sleep in preclinical
models and clinical trials [9-12].
Emerging preclinical and clinical data have suggested
that GABAA receptor modulators and ORAs may differ-
entially impact sleep parameters, particularly with re-
gard to rapid eye movement (REM) sleep. Studies in
rats have demonstrated that the GABAA receptor mod-
ulators eszopiclone and zolpidem disproportionately
promote non─rapid eye movement (NREM) sleep while
suppressing REM sleep. On the other hand, dual orexin
receptor antagonists (DORAs) are known to increase
both REM and NREM sleep [10,13]. Similarly, in human
subjects with situational insomnia, both zolpidem and the
DORA SB-649868 increased total sleep time; SB-649868
reduced REM latency and increased duration compared
with placebo, and zolpidem significantly reduced the pro-
portion of the sleep period spent in REM sleep [14]. Eszo-
piclone and zolpidem also dose-dependently disrupted
sleep-stage─specific electroencephalography (EEG) spec-
tral profiles in rats, even at low doses that do not induce
sleep. In contrast, only the highest dose of DORA-22
tested (30 mg/kg) had marginal effects on EEG power
spectral frequency, and these effects were observed only
during REM sleep [13]. No significant differences in EEG
spectra were observed in clinical trials with suvorexant
(Belsomra®) compared with placebo in both healthy
subjects [15] and in patients with insomnia [16,17].
Zolpidem, but not SB-649868, induced EEG disruptions
in subjects with situational insomnia [14]. The impact
of the observed alterations in sleep architecture with
GABAA receptor modulators, particularly on REM sleep,
remains to be determined.
Chronic total and REM sleep deprivation in rats leads
to significant morbidity and mortality [18]. Even acute
sleep restriction, particularly the suppression of REM
sleep, impacts memory consolidation in preclinical be-
havioral models [19,20]. In humans, anecdotal and clin-
ical evidence suggests that total sleep deprivation may
be associated with cognitive impairments (as reviewed in
Banks and Dinges, 2007, and Basner et al., 2013 [21,22]).The impact of selective REM deprivation in humans is
less clear, but effects on memory consolidation and pain
perception have been reported [23,24].
The present study compared sleep induced by the
standard of care, eszopiclone (a non-benzodiazepine
GABAA receptor modulator) and by two distinct DORAs,
DORA-12 and DORA-22, using polysomnography (PSG)
and quantitative electroencephalography (qEEG) spectral
analysis following dose administration during the active
phase across several species and following REM deprivation
in rats. Direct comparisons with sleep architecture seen
during the normal resting phase revealed that DORAs pro-
portionately induced both NREM and REM sleep in a pat-
tern no different from non-medicated sleep and induced
qEEG changes consistent with those seen during the in-
active phase. Eszopiclone had differential effects on sleep
across species that were characterized by abnormal sleep
architecture and qEEG profiles relative to vehicle-treated,
inactive-phase control animals. Further, DORAs more im-
mediately facilitated proportional recovery sleep following
REM deprivation relative to vehicle or eszopiclone treat-
ment. Co-dosing studies and experiments in orexin/ataxin-
3 (Ox/Atx) transgenic rats lacking orexin neurons indicated
only partial overlap of these two mechanisms.
Results
DORAs and standard of care differentially affect sleep
across mammalian species
To qualitatively compare the sleep architecture induced
by orexin receptor antagonism versus GABAA receptor
modulation across species, PSG analyses were conducted
in telemetry-implanted mice, rats, dogs, and rhesus mon-
keys receiving either DORA-22 or eszopiclone during
their usual active period, and evaluated relative to vehicle
treatment. Representative doses for each species were
chosen based on prior dose response studies inducing sali-
ent, active-wake reduction approximating that seen in
rats, the highest dose tested (DORA-22 in rhesus mon-
keys), or a qEEG effect magnitude similar to that in other
species (eszopiclone in mice, dogs). In all four species ex-
amined, significant active-wake reduction at consecutive
30 min time points by DORA-22 ranged from 2 h (mice)
to 7 h (dogs), and was associated with significant increases
in both NREM and REM sleep (Figure 1A). In mice and
rats, delta sleep showed immediate 2 and 2.5 hour in-
creases (P ≤ 0.05 at four and five consecutive 30 min time
points), respectively, while REM sleep was significantly in-
creased for 3 and up to 5.5 h, respectively. Variable in-
creases in light sleep, comprising the smallest proportion
of vigilance state mean time, were also observed in mice
and to a lesser extent in rats. In dogs and rhesus monkeys,
NREM I sleep was similarly increased with a delay in dogs
at time points up to 7 h after dosing and for 5.5 h in rhe-
sus immediately after dosing coincident with significant
Figure 1 (See legend on next page.)
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Figure 1 Sleep architecture responses to DORA-22 and eszopiclone across species. The mean time spent in each sleep stage during
30-min intervals is plotted for compound (open circles) and vehicle (closed circles) conditions. A. Sleep architecture following DORA-22 treatment
relative to vehicle (vitamin E TPGS [d-alpha tocopheryl polyethylene glycol 1000 succinate], 20% solution, orally) in mice (100 mg/kg, n = 11), rats
(30 mg/kg, n = 13), dogs (3 mg/kg, n = 6), and rhesus monkeys (30 mg/kg, n = 6). SWS I and SWS II refers to lighter NREM I sleep and NREM II
sleep that includes a preponderance of delta qEEG power, respectively. B. Sleep architecture following eszopiclone treatment relative to vehicle
(vitamin E TPGS, 20% solution, orally) in mice (60 mg/kg, n = 6), rats (10 mg/kg, n = 16), dogs (5 mg/kg, n = 6), and rhesus monkeys (10 mg/kg,
n = 6). Time of dose indicated by gray bars. Mean times in each vigilance state during 30-min intervals by condition were averaged over all days
of treatment from a crossover design such that all subjects received each treatment as described in Methods. Significant differences from vehicle
are indicated by gray vertical lines, with black tic marks indicating significance level (short, medium, long, P < 0.05, 0.01, 0.001; linear mixed-effects
model for repeated measures t-test).
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treatment. NREM II was increased in both animals with
dogs showing a greater magnitude change (4.5 h in dogs;
1 hour in monkeys), whereas increases in REM increases
were delayed in both animals (4.5 h in dogs; 30 min in
rhesus) relative to that seen in rodents, likely due to the
slower sleep cycle times in these higher species. The de-
creased magnitude of effects seen in the rhesus monkeys
relative to other species is a result of lower compound
exposure levels for this compound and not the orexin re-
ceptor antagonist mechanism. The maximum plasma con-
centration (Cmax) following 30 mg/kg administration of
DORA-22 to these animals reached 0.14 μM compared to
1.42 μM in rats (30 mg/kg), 3.36 μM in mice (100 mg/kg)
and 1.62 μM in dogs (3 mg/kg) in these experiments.
Eszopiclone, on the other hand, had inconsistent effects
on sleep architecture across species. Attenuation of active
wake was observed in rats (significant time points [p ≤
0.05] for 6 h), rhesus monkeys (3 h), and variably in mice,
but paradoxically was associated with increased arousal in
dogs (3 h of consecutive time points) (Figure 1B). In those
animals in which sleep was induced, compound-dependent
increases were observed in both light sleep (up to 8 h in
rats; 6.5 h in rhesus) and delta or NREM II sleep (up to 5.5
h in rat; 2 h in Rhesus), while mice showed increases in
light sleep (P ≤ 0.05 for 2 h), but variable decreases in delta
sleep. Immediate suppression of REM sleep was common
in rats (2.5 h) and dogs (4 h), but was not observed in mice.
Rhesus monkeys showed no compound-dependent REM
decreases, but minimal baseline levels during the active
phase likely precluded any detectable decrease in these
animals. The increased arousal observed in dogs was con-
sistent with that previously observed at different doses [25]
and similar to that observed for other benzodiazepines
[26-28]. As might be expected, increases in active wake
were associated with decreases in both NREM and REM
sleep in these animals. Together these results demonstrate
variable sleep responses to eszopiclone across species, but
also identify rats as the preclinical species in which the
sleep-promoting effects for both classes of drugs can be re-
liably demonstrated.DORA-induced REM and NREM sleep mimics normal
resting-phase sleep
To determine how the sleep architecture induced by both
classes of drugs compares with that seen during the nor-
mal resting phase, we compared the effects of DORA-12
and eszopiclone administered during the active phase to
the NREM and REM sleep seen normally during the
inactive phase after vehicle dosing in rats. A DORA of dis-
tinct chemical structure, DORA-12 was used herein to
further substantiate the observed effects of DORA-22 on
general inactive-phase sleep effects and qEEG in a prior
sleep-stage analysis [13]. Figure 2 directly compares the
NREM and REM changes occurring during the normal in-
active phase with those seen during the active phase by
shifting the data collected during the normal inactive-
phase onset of 6.5 h to coincide with the active-phase ve-
hicle treatment time (Zeitgeber time [ZT] 17:30; see also
Additional file 1: Figure S1A). As expected, the mean time
spent in NREM and REM following vehicle treatment
during the active phase was significantly lower than that
seen during the 150 min following the onset of the
vehicle treatment inactive phase (NREM: F1,10 = 56.57,
P < 0.0001, 2-way ANOVA, P < 0.0001, Tukey HSD;
REM: F1,10 = 41.19, P < 0.0001, 2-way ANOVA, P < 0.0001,
Tukey HSD). Following active-phase treatment with eszo-
piclone (10 mg/kg), the time course of NREM was signifi-
cantly increased relative to both active-phase vehicle
(F1,10 = 76.72, P < 0.0001, 2-way ANOVA; P < 0.0001,
Tukey HSD) and that occurring during the onset of the
inactive phase (F1,10 = 7.68, P = 0.0197, 2-way ANOVA;
P < 0.0001, Tukey HSD), whereas REM sleep was signifi-
cantly decreased relative to both control conditions (ac-
tive phase: F1,10 = 8.86, P = 0.0139, 2-way ANOVA; P <
0.0001, Tukey HSD; inactive phase: F1,10 = 51.92, P <
0.0001, 2-way ANOVA; P < 0.0001, Tukey HSD). On the
other hand, treatment with DORA-12 (30 mg/kg) dur-
ing the active phase increased both NREM and REM
sleep similar to that observed following vehicle adminis-
tration during the inactive phase onset. Remarkably, the
time courses of these increases were statistically no dif-
ferent from those observed during the inactive-phase
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Figure 2 Sleep architecture induced by DORA-12 is no different
from normal resting-phase sleep in rats. The time course and
magnitude of mean time spent in NREM and REM sleep in 30-min
intervals following active-phase treatment with DORA-12 (30 mg/kg,
n = 14) and eszopiclone (10 mg/kg, n = 16) is compared with that
following vehicle treatment (vitamin E TPGS, 20% solution, orally) at
both the onset of the active phase (Zeitgeber time [ZT] 17:30) and
the inactive phase (ZT 00:00). Values at 30-min intervals are expressed
as percentage of the mean 30-min level calculated from times 90 to
150 min of the inactive-phase onset levels. Data represent a 3-h
summary of the full time course and polysomnographic analysis
presented in Additional file 1: Figure S1; light and delta sleep have
been combined as NREM sleep. Comparison of treatment conditions
analyzed by analysis of variance (ANOVA) followed by the Tukey
multiple comparison (HSD) test revealed significant differences
(P < 0.0001) between all conditions except the following: inactive-
phase onset NREM vs DORA-12 NREM (P = 0.0661), eszopiclone NREM
vs DORA-12 NREM (P = 0.2582), and inactive-phase onset REM vs
DORA-12 REM (P = 0.2933). Similar results were seen when each
condition was evaluated pairwise by 2-way ANOVA: eszopiclone vs
DORA-12 (NREM, F1,10 = 7.43, P = 0.0214; REM, F1,10 = 120.9, P < 0.0001);
active phase vehicle vs DORA-12 (NREM, F1,10 = 26.67, P < 0.0001; REM,
F1,10 = 183.4, P < 0.0001); inactive phase vehicle vs DORA-12 (NREM,
F1,10 = 0.227, P = 0.644, REM, F1,10 = 2.347, P = 0.157); active phase
vehicle vs eszopiclone (NREM, F1,10 = 76.72, P < 0.0001; REM, F1,10 = 8.86,
P = 0.0139); inactive phase vehicle vs eszopiclone (NREM, F1,10 = 7.68,
P = 0.0197; REM, F1,10 = 51.92, P < 0.0001); inactive phase vehicle vs
active phase vehicle (NREM, F1,10 = 56.57, P < 0.0001; REM, F1,10 = 41.19,
P < 0.0001).
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P = 0.644, 2-way ANOVA, P = 0.0661; Tukey HSD; REM:
F1,10 = 2.347, P = 0.157, 2-way ANOVA, P = 0.2933, Tukey
HSD). A comprehensive comparison of the time courses
of vigilance states with vehicle, DORA-12, and eszopiclone
treatments during both the active phase and inactive
phase is shown in Additional file 1: Figure S1; eszopiclone
suppressed REM sleep while promoting NREM sleep in a
manner distinct from that seen during the normal restingphase, whereas DORA-12 induced minimal changes rela-
tive to normal, inactive-phase sleep.
Quantitative EEG analysis in these same rats following
treatment with DORA-12 (30 mg/kg) and eszopiclone
(10 mg/kg) during both the active phase and at the onset
of the resting phase further illustrates differences between
these two mechanisms. DORA-12 administration during
the active phase was associated with time-dependent de-
creases in high-frequency gamma power (30–100 Hz)
(significant time points [P ≤ 0.05] up to 6.5 h following
dosing), increases in middle-frequency spectral power
(theta up to 3 h; alpha, 2.5 h; sigma, 2 h), and little
change relative to vehicle in delta frequency (0.5–4 Hz)
(Figure 3A). These changes largely dissipated 6.5 h later
with the onset of the inactive phase, where DORA-12
responses approached those of vehicle-treated animals.
In contrast, eszopiclone treatment during the active
phase resulted in large increases in qEEG power in the
beta band (19–30 Hz) (12 h) as well as sigma frequen-
cies (12–16 Hz) (5.5 h) whereas minimal decreases were
seen in theta and alpha power (4–7 Hz and 8–12 Hz,
respectively). Relative to vehicle, eszopiclone induced
little-to-no change in gamma and delta powers until the
onset of the inactive phase 6.5 h later, when levels of
gamma, delta, and theta power were maintained even
though vehicle-treated animals exhibited substantial
decreases in gamma power and increases in delta and
theta power associated with sleep onset. These inactive-
phase differences induced by eszopiclone were corrobo-
rated when the drug was administered 1 h prior to the
inactive-phase onset, where substantial changes relative
to the vehicle condition were seen in most frequency
bands (Figure 3B). DORA-12, on the other hand, in-
duced shorter-duration decreases in gamma frequencies
and increases in low-to-mid frequency powers, changes
that exaggerated the normal change displayed in the ve-
hicle condition during the resting period. Overall, both
DORA-12 and eszopiclone appeared to have similar ef-
fects on qEEG power during both the active and inactive
phases, but their observed effects relative to vehicle
were dependent on baseline changes occurring at differ-
ent times of day. Relative to vehicle, DORAs appeared
to have less effect on qEEG power during the inactive
phase, since baseline levels already reflected these changes
during the normal resting period.
DORA-22 promotes recovery from REM sleep deprivation
Given the ability of DORA-22 to promote somnolence
including REM sleep and, conversely, the potential for
eszopiclone to promote sleep associated with REM sup-
pression, we evaluated the ability of both compounds to
promote recovery from REM sleep deprivation. For these
experiments, mice were first subjected to 28 h of REM
deprivation using the platform or “flower pot” paradigm
Figure 3 The qEEG spectral pattern induced by DORA-12 in rats mimics the inactive phase. Mean qEEG spectral power in indicated
frequency bands at 30-min analysis intervals following treatment with DORA-12and eszopiclone (open symbols) was evaluated relative to vehicle
(vitamin E TPGS, 20% solution, orally, closed symbols), coincident with PSG analysis. A. Active-phase (ZT 17:30) treatment with DORA-12 (30 mg/kg,
n = 14) and eszopiclone (10 mg/kg, n = 16). B. Treatment 1 h prior to the inactive-phase onset (ZT 23:00) with DORA-12 (30 mg/kg, n = 7) and eszopiclone
(10 mg/kg, n = 8). Gray vertical bars represent dose time. Significant differences from vehicle are indicated by gray vertical lines; black tic marks
indicate significance level (short, medium, long, P < 0.05, 0.01, 0.001; linear mixed-effects model for repeated measures t-test).
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of vehicle (vitamin E TPGS [d-alpha tocopheryl polyethyl-
ene glycol 1000 succinate], 20% solution, p.o.), DORA-22
(100 mg/kg) or eszopiclone (60 mg/kg), or no treatment.
This manipulation involves placing mice in cages contain-
ing 3-cm-diameter platforms surrounded by water (REM
deprivation condition), such that the atonia accompanying
REM sleep is associated with the animals slipping into the
water and arousing. In initial control experiments to dem-
onstrate the feasibility of this approach, mice in cages con-
taining pedestals with water were compared with mice
housed similarly, but in the absence of water. As expected,
mice in the REM deprivation condition exhibited signifi-
cant reductions in the amount of time spent in REM sleep
at time points throughout the duration of the manipula-
tion (Figure 4A). Upon transfer to cages containing nor-
mal bedding at ZT 0:00, a condition representing a novel
environment, both control and REM-deprived animals
exhibited maximal active wake for approximately 1 h
(Figure 4B). Shortly thereafter, mean time in active wake
began to decrease in both groups with the REM-deprived
group exhibiting significantly less active wake at 3 time
points, and increased delta sleep at early time points. Simi-
larly, REM sleep also increased in both groups with the
REM deprivation group exhibiting more REM recovery
relative to those in the control condition. The administra-
tion of DORA-22 occurred simultaneously with thetransfer of animals to normal conditions and induced im-
mediate active-wake attenuation coincident with increases
in both delta and REM sleep, relative to vehicle-treated
animals (significant changes at 1 hour and 50 min relative
to vehicle) (Figure 4C). Unlike the changes seen during
normal recovery, these changes occurred within 10 min
after transfer to cages containing normal bedding. Eszopi-
clone also facilitated active-wake reductions for 1 hour
immediately upon return to normal cages following REM
deprivation (Figure 4D). However, in contrast to DORA-
22 treatment, this manipulation was associated with in-
creases in light and delta sleep at early time points with
little change in REM sleep. Even in what was expected to
be increased REM pressure, this GABAA receptor modu-
lator significantly suppressed REM at later time points
relative to vehicle-treated animals.
GABAA modulators suppress REM independently of orexin
signaling
To determine the interaction between GABAA receptor
modulator and DORA-mediated mechanisms, and the
dependence of eszopiclone activity on orexin signaling,
we first evaluated the effectiveness of both DORA-22
(30 mg/kg) and eszopiclone (10 mg/kg) in Ox/Atx trans-
genic rats deficient in orexin neurons (expressing the
cytotoxic poly-Q-ataxin-3 gene product via the HCRT
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A   REM Deprivation
Figure 4 DORA-22 facilitates REM recovery following REM deprivation. A. REM deprivation in mice utilizing the pedestal method for 28 h
(ZT 20:00 to ZT 24:00/00:00 on the subsequent day, n = 8 wild-type C57/BL6 mice in a balanced 2 × 1 day crossover). B. Sleep architecture at the
cessation of 28 h of REM deprivation. Mice were alternately housed in cages containing pedestals and either no water (control condition, closed
symbols) or water (REM deprivation condition, open symbols) in a balanced 2 × 1 day crossover as described in Methods (n = 8 wild-type
C57/BL6 mice). Time spent in the indicated sleep stages immediately upon cage change to normal bedding (ZT 00:00, or lights-on) is shown.
C. Effects of DORA-22 treatment (100 mg/kg p.o., open symbols) relative to vehicle (vitamin E TPGS, 20% solution, orally, closed symbols) on sleep
architecture when administered coincident with the cessation of REM deprivation (ZT 00:00, n = 11 wild-type C57/BL6 mice in a balanced 2 ×
1 day crossover in which each animal alternately received vehicle and DORA-22). D. Effects of eszopiclone treatment (60 mg/kg p.o., open
symbols) relative to vehicle (vitamin E TPGS, 20% solution, orally, closed symbols) coincident with the cessation of REM deprivation (ZT 00:00,
n = 11 wild-type C57/BL6 mice in a balanced 2 × 1 day crossover in which each animal alternately received vehicle and eszopiclone). Significant
differences are indicated by gray vertical lines, and black tic marks indicate significance level (short, medium, long, P < 0.05, 0.01, 0.001).
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22 resulted in diminished, but still detectable responses
in Ox/Atx transgenic rats (Figure 5A), consistent with
the diminished, yet incomplete, ablation of orexin signaling
in this model (the selectivity of DORA-22 at 100 mg/kg
has previously been demonstrated in mice lacking both
OX1R and OX2R [12]). The sleep-promoting effects of
eszopiclone were also diminished in Ox/Atx transgenic ratsrelative to the effects seen in wild-type Sprague–Dawley
rats (Figure 5B), the exception being in the magnitude of
REM reduction where significant reductions were seen up
to 4 h post administration. Together these results suggest
that eszopiclone mediates many of its sleep-promoting re-
sponses through orexin signaling with the exception of its
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Figure 5 Sleep architecture induced by DORA-22 and eszopiclone in wild-type and OX/Atx transgenic rats. A. PSG analysis of DORA-22
(30 mg/kg) relative to vehicle (vitamin E TPGS, 20% solution, orally) in wild-type (n = 7) and Ox/Atx (n = 7) Sprague–Dawley rats. B. PSG analysis of
eszopiclone (10 mg/kg) relative to vehicle (vitamin E TPGS, 20% solution, orally) in wild-type (n = 7) and Ox/Atx (n = 7) Sprague–Dawley rats. Significant
differences are indicated by gray vertical lines, and black tic marks indicate significance level (short, medium, long, P < 0.05, 0.01, 0.001).
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ing may be largely redundant in their control of active
wake and NREM sleep but diverge in their control of
REM, the impact of combined administration of DORA-
22 (30 mg/kg) and eszopiclone (10 mg/kg) on sleep pa-
rameters compared with administration of each agent
alone was evaluated in wild-type rats. Relative to DORA-
22 alone, the combination exhibited non-additive effects
on active-wake reduction (biphasic 1.5 hour increase
followed by 1 hour decrease) and only marginal increases
in light and delta sleep (Figure 6A). REM sleep, however,
was substantially reduced by combination treatment for
2.5 h following treatment. Compared with eszopiclone
alone, the combination induced no clear decreases in ac-
tive wake or increases in delta sleep with the possible ex-
ceptions of light and REM sleep (Figure 6B). Transient
reductions in light sleep (1 hour) suggested a small influ-
ence of DORA-22 to counter the activity of eszopiclone.
The combination of DORA-22 and eszopiclone, however,
did significantly increased REM sleep relative to eszopi-
clone alone for up to 3.5 h following treatment. Together
these results demonstrate that the pathways underlyingthe influence of orexin receptor antagonism on sleep
parameters overlap with those of the GABAA receptor
modulator with the exception of REM sleep, which ap-
pears to be mediated by distinct pathways.
Discussion
These analyses demonstrate that DORAs promote sleep
architecture that is indistinguishable from normal resting-
phase sleep in animal models, utilizing a mechanism that is
distinct from the GABAA receptor modulator, eszopiclone.
DORAs have been previously shown to promote NREM
and REM sleep proportionately across mammalian species,
including man [10-12,14-16]. Here we demonstrate that the
sleep architecture promoted by DORA-12 during both the
active and inactive phase closely mimics that seen during
the normal resting phase following vehicle treatment,
whereas eszopiclone suppresses REM sleep to levels below
those seen even during the active phase (see Figure 2).
Notably, both NREM and REM sleep induced by DORA-
12 at 30 mg/kg is similar in both magnitude and time
course to normal inactive-phase sleep. Further, the qEEG
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Figure 6 The combination of DORA-22 and eszopiclone exhibits
non-additive effects relative to either agent alone. Vehicle
(vitamin E TPGS, 20% solution, orally), DORA-22 (30 mg/kg), and
eszopiclone (10 mg/kg) were dosed alone, or DORA-22 and eszopiclone
were administered concomitantly in rats (n = 14) during the active phase
(ZT 17:00, gray bar) in the following paradigm: 3 consecutive days of
vehicle, 3 days of eszopiclone alone, 3 days of eszopiclone plus DORA-
22, and 3 days of DORA-22 alone. Data from all days of each condition
were averaged and plotted in 30-min intervals. A. Comparison of
responses to DORA-22 (closed symbols) relative to the combination
of DORA-22 plus eszopiclone (open symbols). B. Comparison of
responses to eszopiclone (closed symbols) relative to the combination
of DORA-22 plus eszopiclone (open symbols). Significant differences at
30-min intervals were determined using a linear mixed-effects model
for repeated measures t-test, where significant responses are indicated
by gray lines and tic marks indicate significance level (short, medium,
long, P < 0.05, 0.01, 0.001).
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across frequency bands, the differences being an augmenta-
tion of increases in lower frequencies and decreases in
higher frequencies typically associated with normal resting-
phase sleep. While specific qEEG frequency band defini-
tions (the frequency range assignment [in hertz] of delta,
theta, alpha, sigma, beta, and gamma bands) can differ be-
tween species and laboratories, it is clear from these studies
that the pattern of qEEG changes induced by DORA-12 is
similar, if not indistinguishable, from that seen during the
resting phase, regardless of band definitions. Eszopiclone
responses, on the other hand, exhibit substantial differences
from what is typically seen during the resting phase,including dramatically increased beta power, increased
gamma power, and decreased lower-frequency alpha, delta,
and theta power, the latter potentially being associated with
REM suppression. Our qEEG findings corroborate prior
evaluations in rats and humans, in which DORA-22 and
SB-649868 each minimally disrupted sleep-stage–dependent
qEEG spectral power in comparison with the GABAA
receptor modulators, which substantially disrupted qEEG
spectral power in both the active and inactive phases
[13,14]. In fact, a recently published clinical study demon-
strated that suvorexant minimally impacts qEEG spectral
density during NREM and REM sleep relative to placebo in
both healthy subjects and insomnia patients while trazadone
and the GABAA receptor modulators, zolpidem and gabox-
adol, induced distinct profiles in human subjects [31].
It has been suggested that the REM promotion by
DORAs exceeds what might be expected for normal
sleep [32,33], yet these assertions have been made in
studies that lack a specific characterization of the time
course and magnitude of REM sleep during the normal
resting phase. By superimposing the sleep architecture
observed during the inactive phase following vehicle
treatment with that occurring during the active phase
following vehicle treatment here, we have been able to
demonstrate that both NREM and REM sleep increase
substantially with the onset of sleep in rats, and that
DORA-12 increases both vigilance states in a way that is
similar to that seen normally at the onset of the inactive
phase (see Figure 2; Additional file 1: Figure S1). Further,
it is unclear what detrimental effects may result from nor-
mal or moderate increases in REM sleep during the in-
active phase, and any causal relationships with behavior
have yet to be demonstrated. On the other hand, it is clear
that REM deprivation is associated with physiological and
cognitive deficits. In rats, REM sleep deprivation by the
disk-over-water method is associated with a severe pheno-
type characterized by weight loss with paradoxical hyper-
phagia, impaired thermoregulation, and eventual fatality
[18,34,35]. Selective REM deprivation has also been shown
to have hyperalgesic effects in sleep laboratory studies
[24]. Perhaps the most well-studied effects are on impair-
ments in learning and memory in rats; REM deprivation
impairs hippocampus-dependent spatial learning, and is
associated with molecular and cellular alterations in hip-
pocampal function [19,20,36-38]. In fact, a recent study
examining the effects of zolpidem in human subjects
found that deficits in memory improve the day following
administration, a time at which drug levels were expected
to have diminished, interpreted to suggest that the quality
of sleep induced by this GABAA receptor modulator af-
fects cognitive performance [39].
On the other hand, our REM deprivation studies in
mice demonstrate that DORA-22 effectively promotes
both delta and REM sleep immediately upon transfer
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ding, a recovery that was more immediate than in un-
treated control mice. In this paradigm, transfer to a
normal cage represents a novel environment such that
untreated control mice continue to exhibit arousal for
up to an hour. Both DORA-22 and eszopiclone signifi-
cantly attenuated active-wake phase immediately upon
transfer to the recovery condition, but DORA-22 facili-
tated REM recovery while eszopiclone actually suppressed
REM sleep at later time points relative to vehicle despite a
presumed homeostatic drive for REM recovery. In
untreated control mice, delta sleep increased with a
time course that preceded REM-sleep increases, while
DORA-22 increased REM nearly coincident with delta
sleep, suggesting that DORAs may facilitate recovery in
response to homeostatic drive. Indeed, it has been
suggested that the OX1R antagonism provided by
DORAs may allow for disinhibition of REM sleep [33],
which may underlie yet another favorable property of
DORAs in their ability to respond to accumulated REM
sleep debt. If this is indeed the case, variability in sleep
architecture, including the magnitude and timing of
REM sleep promotion observed in animal models at
different laboratories, would be expected to be a func-
tion of the prior housing conditions; differences in total
sleep debt or specific sleep stage debt in EEG-implanted
mice or rats would be expected to give rise to differ-
ences in responses to DORA treatment. Further study is
required to determine the ability of both ORAs and
GABAA receptor modulators to respond to homeostatic
needs and the behavioral and psychiatric consequences
resulting from those manipulations.
The hypnotics compared herein – GABAA receptor
modulators and DORAs – promote sleep via distinct,
but overlapping mechanisms of action. Orexin neurons
and their cognate receptors are more discretely distrib-
uted in the brain relative to GABAA receptor subtypes,
and targeting orexin-mediated arousal with ORAs has
more restricted effects relative to the GABAA receptor
modulators, which augment GABAA receptor activity,
resulting in widespread central nervous system depres-
sion. Within the sleep system, orexin neuron activity
promotes arousal and vigilance-state control through
their projections to tuberomammillary nuclei and brain
stem structures including the dorsal raphe, locus coeru-
leus, and laterodorsal and pedunculopontine tegmental
nuclei, while inhibitory GABAergic projections from
ventrolateral preoptic nuclei project to many of the same
structures as well as orexin neurons [40]. However, the
widespread distribution and function of GABAA receptor
subtypes involved in other complex behaviors—including,
but not limited to anxiety, locomotor coordination, addic-
tion, learning, and memory [41,42] —may underlie the
differential sleep-promoting effects of GABAA receptormodulators across species (e.g., sleep promotion in rats,
monkeys, and humans, but paradoxical hyperarousal in
dogs). Species-dependent differences in signal strength
mediated by the multitude of GABAergic pathways
within and/or outside of the specific sleep pathways are
likely responsible. Nevertheless, our findings indicate
overlap between orexin and GABAergic pathways, as
might be predicted from histological evidence. The
sleep effects of DORA-22 were markedly attenuated in
orexin neuron─deficient rats, indicating that these ef-
fects were mediated through the orexin pathway with
some remaining effects likely due to incomplete abla-
tion of orexin-containing neurons in these animals [30].
The selectivity of DORA-22 has previously been dem-
onstrated at doses as high as 100 mg/kg in mice lacking
both orexin receptors, where no detectable effects were
seen [12]; as such, the residual REM promotion seen in
Ox/Atx transgenic rats is likely due to residual orexin
signaling in those animals. The effect of eszopiclone on
active wake and NREM sleep was also attenuated in rats
lacking orexin neurons, and the combined administra-
tion of both agents had similar effects on active wake
compared with either administered alone. These results
suggest that both classes of compounds reduce active
wake through a common pathway. REM sleep, however,
was similarly suppressed by eszopiclone in both Ox/Atx
transgenic rats and in wild-type control rats. The com-
bined administration of eszopiclone with DORA-22
markedly reduced REM relative to DORA-22 alone, and
only slightly increased REM relative to eszopiclone
alone, indicating that these effects on REM sleep are
not entirely additive. Both orexinergic and GABAergic
signaling influence the activity of brainstem nuclei, par-
ticularly the locus coeruleus, to affect vigilance-state
control, including REM sleep. These results indicate
that these influences are not entirely dependent on one
another, but can influence this function through parallel
means. From a therapeutic standpoint, these overlap-
ping, yet distinct mechanisms have important implica-
tions regarding tolerance and dependence. GABAA
receptor modulators have been shown in both animal
models and human subjects to exhibit tolerance to
repetitive dosing, becoming less efficacious over time
[43-45], while ORAs, including suvorexant (Belsomra®),
have shown no tolerance or evidence of withdrawal
even after a year of treatment in patients [17] and no
diminution of efficacy in animal models (reviewed in
[46]). While the role of orexin in reward and withdrawal
suggest that ORAs may have the capacity to diminish
the dependence on rewarding influences (reviewed in
[47]), the effectiveness of ORAs in animal models and
human subjects following treatment with the current
standard of care, GABAA receptor modulators, remains
to be determined.
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While no major differences in PSG and qEEG profiles
were observed during DORA-induced sleep in this study,
eszopiclone had marked effects on PSG and qEEG pro-
files, suggesting that GABAA receptor modulators may
have effects that do not resemble natural sleep or qEEG
patterns. The observed effects of eszopiclone on REM
sleep, but not active wake and NREM sleep in OX/Atx
mice or in the presence of co-administered DORA-22,
support the idea that eszopiclone and DORA-22 impact
REM sleep via divergent pathways but may share a com-
mon (orexin-dependent) mechanism for their influence
on active wake and NREM sleep. The potential for ORAs
to promote sleep in a way that is qualitatively similar to
natural sleep suggests that orexin receptor antagonists
may have promise as a novel therapeutic for insomnia.
Methods
Animals and compound administration
All animal experiments were performed in accordance
with The National Research Council’s Guide for the Care
and Use of Laboratory Animals (http://www.nap.edu/
catalog.php?record_id=12910) and were approved by the
Merck Institutional Animal Care and Use Committee.
All efforts were made to minimize animal use and suffer-
ing. The animals were singly housed with food and water
available ad libitum, and on a 12:12 light:dark cycle. All
compounds were administered orally at the indicated dos-
ages in vitamin E TPGS, 20% solution.
In adult male C57/BL6NTac wild-type mice (ages 9 to
14 weeks; Taconic Farms, Germantown, NY), DORA-22
(100 mg/kg), eszopiclone (60 mg/kg), or vehicle were ad-
ministered during the active (dark) phase 4 h prior to
lights-on (ZT 20:00, where ZT 00:00 is lights-on). Treat-
ments were administered for 5 days in a balanced cross-
over design (5 days of compound or vehicle, followed by
a 2-day washout and 5 days of conditional crossover),
and the compound and vehicle conditions for each animal
were combined and averaged over a 24-h time period be-
fore determining the effects relative to vehicle.
Adult male Sprague–Dawley wild-type rats (c.a. 600 g;
6–12 months of age; Taconic Farms, Germantown NY)
were treated with DORA-22 (30 mg/kg), DORA-12
(30 mg/kg), eszopiclone (10 mg/kg), or vehicle during
the active (dark) phase (7 h prior to lights-on, ZT 17:00)
or inactive (light) phase (1 h prior to lights-off, ZT
23:00) in a balanced crossover design (1–2 days of ve-
hicle run-in [all], 3 days on vehicle or compound treat-
ment, 2–3 days of washout, 3 days on reverse arm). The
orexin/ataxin-3 (Ox/Atx) rats, which exhibit postnatal
loss of orexin neurons, have been described elsewhere
[48] and were licensed from the University of Texas
Southwestern Medical Center and maintained at Taconic
Farms, Germantown NY.Adult male beagles (9–17 kg; Marshall BioResources,
North Rose, NY) were treated with DORA-22 (3 mg/kg)
or eszopiclone (5 mg/kg) during the active phase 9 h
prior to lights-off (ZT 03:00). Cognitive testing was per-
formed 2.5 to 3 h following DORA-22 treatment, but
found no differences from vehicle in PSG or qEEG record-
ings (not shown). For PSG analysis, a block repeated-
measured design was employed, in which all dogs received
vehicle for 5 days, followed by a 2-day washout and 5 con-
secutive days of DORA-22 treatment.
Adult male rhesus monkeys (Macaca mulatta, 6.9 −
13 kg; The Mannheimer Foundation, Homestead, FL, Cov-
ance Research Products, Denver, PA, and the University of
Louisiana at Lafayette, Lafayette, LA) were treated with
DORA-22 (30 mg/kg), eszopiclone (10 mg/kg), or vehicle
during their active phase (6.5 h prior to lights-off, ZT
05:30). A 1-day block crossover design was used, in which
all subjects received 1 day of vehicle and 1 day of com-
pound treatment.
Sleep architecture and qEEG recordings
The durations of sleep stages were quantitated by PSG in
mice and rats subcutaneously implanted with radio tele-
metric physiologic monitors (Data Sciences International,
Arden Hills, MN) to simultaneously record continuous
electrocorticogram (ECoG) and electromyogram (EMG)
activities, as previously described [11,12]. Polysomnogra-
phy was performed in telemetry-implanted dogs and
rhesus monkeys via ECoG, EMG, and electrooculogram
(EOG), as described previously [11,49]. Sleep scoring and
methods for determining differences in the amount of
time spent in active wake and various sleep stages (light,
delta, and REM sleep in mice and rats; NREM I/SWS I,
NREM II/SWS II, and REM in dogs and rhesus monkeys)
has been described in detail elsewhere [11,13,50].
Quantitative EEG scoring was performed on ECoG
data collected during sleep experiments from telemetry-
implanted C57/BL6 mice, Sprague–Dawley rats, beagles,
and rhesus monkeys with modifications to that previously
described [13]. Briefly, spectral analysis of continuous
EEG was quantified for vehicle and compound conditions
after scoring continuous frequencies into canonical fre-
quency bands (delta, 0.5–4 Hz; theta, 4.0–7.0 Hz; alpha,
8.0–12 Hz; sigma, 12–16 Hz; beta, 19–30 Hz; and gamma,
35.0–100.0 Hz). Quantitative EEG values are spectral
power (uV2) log transformed before analysis and averaged
over 30-min intervals. Results are expressed as means ±
standard error of the mean (SEM). Comparisons with
vehicle were performed using a mixed-model analysis of
variance (ANOVA) at each time point with random ef-
fects for subject and date within subject in the R statis-
tical computing environment (cran.us.r-project.org; the
R Foundation for Statistical Computing, Vienna, Austria).
A linear mixed-effects model was used for significance
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min intervals are indicated in the corresponding figures
with gray vertical lines through significantly different data
points and tic marks indicating significance level (short,
medium, long, P < 0.05, 0.01, 0.001).
REM deprivation and recovery in mice
REM deprivation in mice was performed using modifica-
tions to the “flower pot” method previously described
[29]. Cages were prepared that contained four cylindrical
pedestals (3 cm in diameter × 2.5 cm tall) fixed to the
bottom of the enclosure, roughly equidistant from one
another, allowing mice to move from one location to an-
other within the cage to access food and water. Under
deprivation conditions, water was added to the bottom
of the cage to a height of approximately 2 cm such that
REM sleep − induced atonia was associated with water
exposure and immediate arousal. Control conditions in-
cluded cages containing pedestals without water. In all
experiments, the deprivation (or no water control) condi-
tion proceeded for 28 h beginning at ZT 20:00 (late active
phase) to ZT 24:00/00:00 (inactive-phase onset) on the
subsequent day at which time the animals were returned
to cages containing normal Bed o’ Cobb bedding to allow
recovery sleep. All experiments were separated by at least
3 days of normal bedding conditions.
REM deprivation and recovery in the absence and
presence of pharmacological treatment was performed in
telemetry-implanted mice in which vigilance state was
evaluated continuously (PSG described above). Experi-
ments utilized a 2 × 3 day balanced crossover design in
which each animal experienced both the control and ex-
perimental conditions on alternative arms of the experi-
ment. In baseline studies measuring recovery after REM
deprivation, the first arm of these experiments was initi-
ated with 28 h of deprivation or control conditions (pedes-
tal cages with or without water, respectively), followed by
44 h of recovery (28 + 44 = 72 h, or 3 days), and continued
with a second 28-h deprivation and 44-h recovery period.
After an additional day of washout, the second arm of the
study proceeded identically to the first except that the
experimental and control groups were reversed such that
each animal received both treatments. In experiments
evaluating the impact of DORA-22 and eszopiclone on
REM recovery, all animals experienced deprivation for
28-h periods followed by REM recovery, at which time ve-
hicle and drug (DORA-22 or eszopiclone) were adminis-
tered in the 2 × 3 day balanced crossover design described
above. REM recovery was evaluated in 10-min intervals
following return to cages containing normal bedding.
Statistical analyses
Statistical comparison of control and experimental con-
ditions at individual time points in PSG and qEEGexperiments (Figures 1, 3, 4, 5 and 6) was determined
using a linear mixed-effects statistical model with re-
peated measures analysis of variance (ANOVA) applied
using the R statistical software application (cran.us.r-
project.org; the R Foundation for Statistical Computing,
Vienna, Austria, v3.0.1; nlme package v3.1-111) with
fixed effects for treatment and random effects for subject
at each time point to identify points of statistical signifi-
cance. Biological/pharmacological significance was sub-
sequently determined by consecutive significance points
(P < 0.05) with similar sequential trend. Gray vertical
lines indicate treatment differences of p < 0.05 with verti-
cal black segment lines indicating level of significance
(short: P < 0.05; medium: P < 0.01; long: P < 0.001). Sig-
nificant differences in responses between multiple con-
ditions over a defined time period (150 min for the
experiments in Figure 2) were determined in the R statis-
tical software application by two different methods and
are reported separately. The first evaluated data combined
from all four conditions by repeated measures ANOVA
followed by Tukey multiple comparison (HSD) test to de-
termine significant differences between each condition. A
second method compared individual conditions in a pair-
wise manner by repeated measures ANOVA to determine
the F statistic and P value for each of six comparisons be-
tween four conditions.
Additional file
Additional file 1: Figure S1. Showing detailed sleep architecture
comparisons between active- and inactive-phase sleep following vehicle
treatment, as well as active- and inactive-phase sleep architecture following
treatment with DORA-12 (30 mg/kg) and eszopiclone (10 mg/kg), is
supplied as supporting data to that summarized in Figure 2.
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